Cargando…

Coronavirus Disease 2019 and Acute Kidney Injury: What Have We Learned?

Detalles Bibliográficos
Autores principales:	Husain-Syed, Faeq, Birk, Horst-Walter, Ronco, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927672/ https://www.ncbi.nlm.nih.gov/pubmed/33686376 http://dx.doi.org/10.1016/j.ekir.2021.02.035

Ejemplares similares

Management of acute kidney injury in patients with COVID-19
por: Ronco, Claudio, et al.
Publicado: (2020)

Lung-Kidney Cross-Talk
por: Husain-Syed, Faeq, et al.
Publicado: (2019)

Advances in laboratory detection of acute kidney injury
por: Husain-Syed, Faeq, et al.
Publicado: (2022)

Commentary: Extracorporeal membrane oxygenation for patients with refractory Coronavirus Disease 2019 (COVID-19): What do we know and what do we need to learn?
por: Jacobs, Jeffrey P., et al.
Publicado: (2022)

Commentary: Coronavirus disease 2019 in cardiac surgery: We are still learning and have yet to see all possible complications
por: Ramzy, Danny
Publicado: (2020)

Gene expression in human sepsis: what have we learned?
por: Russell, James A
Publicado: (2011)

Acute kidney injury in neurocritical care
por: Husain-Syed, Faeq, et al.
Publicado: (2023)

Acute kidney injury: from clinical to molecular diagnosis
por: Ronco, Claudio
Publicado: (2016)

Stroke Risk Related to Coronavirus Disease-2019: What Have We Learned?
por: Pourciau, Pamela, et al.
Publicado: (2023)

Commentary: Thoracoscopic-Assisted Rib Plating: Where We Are and What We Have Learned
por: Kim, Seon Hee, et al.
Publicado: (2023)

Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives
por: Husain‐Syed, Faeq, et al.
Publicado: (2020)

Biomarkers for acute kidney injury: is NGAL ready for clinical use?
por: Ronco, Claudio
Publicado: (2014)

Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform to Enhance Lung-Protective Ventilation in Hypercapnic Patients With Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome
por: Husain-Syed, Faeq, et al.
Publicado: (2020)

Commentary: What do we still have to learn from surgery?
por: Belluschi, Igor, et al.
Publicado: (2021)

The Coronavirus Disease 2019 (COVID-19) Pandemic in Africa: What Can We Expect?
por: Maoujoud, Omar, et al.
Publicado: (2020)

What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus?
por: Chen, Yusha, et al.
Publicado: (2020)

Acute kidney injury and residual renal function
por: Ronco, Claudio, et al.
Publicado: (2012)

Acute kidney stress—a useful term based on evolution in the understanding of acute kidney injury
por: Katz, Nevin, et al.
Publicado: (2016)

The concept of risk and the value of novel markers of acute kidney injury
por: Ronco, Claudio, et al.
Publicado: (2013)

Controversies in acute kidney injury: the 2011 Brussels Roundtable
por: Kellum, John A, et al.
Publicado: (2011)

What have we learned from cancer immunotherapy in the last 3 years?
por: Ascierto, Paolo A, et al.
Publicado: (2014)

History of gestational diabetes and future cardiovascular disease: What have we learned?
por: Hsu, Cherng‐Lan, et al.
Publicado: (2018)

COVID-19 and patient engagement in health research: What have we learned?
por: Denegri, Simon, et al.
Publicado: (2021)

Commentary: Patient Perspectives on Artificial Intelligence; What have We Learned and How Should We Move Forward?
por: Camaradou, Jennifer Catherine Louise, et al.
Publicado: (2023)

Coronavirus Disease 2019 Outbreak in a Psychiatric Closed Ward: What We Have to Learn
por: Chun, June Young, et al.
Publicado: (2021)

Acute kidney injury in the intensive care unit: current trends in incidence and outcome
por: Cruz, Dinna N, et al.
Publicado: (2007)

Targeting cytokine storm in COVID-19: what have we learned?
por: Ridker, Paul M
Publicado: (2021)

Coronavirus Disease 2019-Associated Acute Kidney Injury Garners More Attention
por: Yan, Meihua, et al.
Publicado: (2021)

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
por: Tang, Jordan, et al.
Publicado: (2011)

Qualitative research on community experiences in large HIV research trials: what have we learned?
por: Camlin, Carol S, et al.
Publicado: (2018)

Estimating maternal mortality: what have we learned from 16 years of surveys in Afghanistan?
por: Alba, Sandra, et al.
Publicado: (2020)

Clinical trials for coronavirus disease 2019: What is being evaluated and what is not
por: Arabi, Yaseen M., et al.
Publicado: (2020)

Continuous Renal Replacement Therapy in the Critically Ill Patient: From Garage Technology to Artificial Intelligence
por: Samoni, Sara, et al.
Publicado: (2021)

Violence against children in the time of COVID-19: What we have learned, what remains unknown and the opportunities that lie ahead
por: Fore, Henrietta H.
Publicado: (2021)

Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?
por: Ewer, Michael S., et al.
Publicado: (2016)

Clinical trial registration during COVID-19 and beyond in the African context: what have we learned?
por: Mathebula, Lindi, et al.
Publicado: (2022)

Metasynthetic Madness: What Kind of Monster Have We Created?
por: Thorne, Sally
Publicado: (2016)

Rationale for sequential extracorporeal therapy (SET) in sepsis
por: Ronco, Claudio, et al.
Publicado: (2023)

Time-restricted feeding: what we have done and what more we can do?
por: Sun, Yuning, et al.
Publicado: (2023)

When should we start renal-replacement therapy in critically ill patients with acute kidney injury: do we finally have the answer?
por: Bagshaw, Sean M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_frickcm8r2blv0thvc4v0ctmdn